Luteinizing Hormone (LH) Supplementation in Gonadotropin-releasing Hormone (GnRH) Antagonist Cycles
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Ovarian Stimulation
- Sponsor
- Instituto Valenciano de Infertilidad, IVI VALENCIA
- Enrollment
- 720
- Locations
- 1
- Primary Endpoint
- Implantation rate
- Status
- Completed
- Last Updated
- 16 years ago
Overview
Brief Summary
To analyse the impact on cycle outcome of LH supplementation in ovarian stimulation controlled with a GnRH antagonist in two ages groups: patients upto 35 years old, and patients aged between 36 and 39 years old.
Detailed Description
All patients received an oral contraceptive pill with 0.030 mg of ethinyl-estradiol and 3.0 mg of drospirenone the cycle prior to ovarian stimulation. On the second day of menstruation, patients started ovarian stimulation as follows: Patients \< 36: 225 IU/day of recombinant FSH (FSH alone group) or 150 IU of rFSH and 75 IU of rLH/day (FSH+LH group) for 5 days. On day 6, a 0.25 mg/day dose of the GnRH antagonist Cetrorelix is added until the day of rCG administration. Patients 36-39: Initial dose of 300 IU of rFSH /day (FSH alone group)) or 225 IU of rFSH and 75 IU of rLH/day (FSH + LH group) for 5 days. On day 6, a 0.25 mg/day dose of the GnRH antagonist Cetrorelix is added until the day of rCG administration. A maximum of 3 embryos were transferred on day 3 of embryo development.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1st-2nd IVF cycle.
- •Age until 39 years old
- •BMI: 18-29.
- •Basal FSH \< 12 IU/L
Exclusion Criteria
- •LH:FSH \> 2 (PCO)
- •Low response background (\< 5 oocytes)
- •Endometrioma
- •Recurrent pregnancy loss
- •Any preimplantational genetic diagnosis indication
- •Any systemic, metabolic or endocrinological disorder.
Outcomes
Primary Outcomes
Implantation rate
Time Frame: 4 weeks after embryo transfer